All In Biotech

Drug Trial Radar · NCT06417814

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants With EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Has Progressed on Prior Osimertinib Treatment (TROPION-Lung15)

Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 768 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

768

Actual

Start

Oct 4, 2024

Primary completion

Jan 11, 2027

Study completion Sep 27, 2028

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Daiichi Sankyo
First posted
May 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the effect of Dato-DXd in combination with osimertinib or Dato-DXd monotherapy versus platinum-based doublet chemotherapy in terms of progression-free survival (PFS).

Conditions

  • Metastatic Non-small Cell Lung Cancer

Interventions

  • Dato-DXdDrug

    Dato-DXd will be administered as IV infusion.

  • OsimertinibDrug

    Osimertinib will be administered orally.

  • PemetrexedDrug

    Pemetrexed will be administered as IV infusion.

  • CarboplatinDrug

    Carboplatin will be administered as IV infusion.

  • CisplatinDrug

    Cisplatin will be administered as IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free Survival (PFS)Time frame: Up to 2.5 years

Locations

211 sites in 24 countries. Site status is shown where the registry gives one.

  • Research Site

    Fayetteville, Arkansas

  • Research Site

    Fountain Valley, California

  • Research Site

    San Diego, California

  • Research Site

    Jacksonville, Florida

  • Research Site

    Kansas City, Missouri

  • Research Site

    New York, New York

  • Research Site

    Maumee, Ohio

  • Research Site

    Pittsburgh, Pennsylvania

  • Research Site

    Nashville, Tennessee

  • Research Site

    Fitzroy, Australia

  • Research Site

    Heidelberg, Australia

  • Research Site

    Kogarah, Australia

  • Research Site

    Liverpool, Australia

  • Research Site

    Nedlands, Australia

  • Research Site

    St Leonards, Australia

  • Research Site

    Westmead, Australia

  • Research Site

    Woolloongabba, Australia

  • Research Site

    Charleroi, Belgium

  • Research Site

    Edegem, Belgium

  • Research Site

    Ghent, Belgium

  • Research Site

    Hasselt, Belgium

  • Research Site

    Jette, Belgium

  • Research Site

    Namur, Belgium

  • Research Site

    Roeselare, Belgium

  • Research Site

    Barretos, Brazil

  • Research Site

    Betim, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Rio de Janeiro, Brazil

  • Research Site

    Rio de Janeiro, Brazil

  • Research Site

    Rio de Janeiro, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    Brampton, Ontario, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Québec, Quebec, Canada

  • Research Site

    Baoding, China

  • Research Site

    Beijing, China

  • Research Site

    Beijing, China

Showing 40 of 211 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.